

Completion of 500 million JPY Series B financing

TAGCys Biotechnologies Inc. (Tokyo, Japan) has raised 500 million JPY in Series B financing as of 24th April 2018, from four venture capital firms, the University of Tokyo Edge Capital Co., Ltd. (UTEK) (Tokyo), SMBC Venture Capital Co., Ltd. (Tokyo), UTokyo Innovation Platform Co., Ltd. (Tokyo) and Mizuho Capital Co., Ltd. (Tokyo).

TAGCyx is developing unique DNA aptamer called “Xenoligo™” in healthcare field, using proprietary artificial nucleic acid base pair. Xenoligo™ is believed to have significant advantages over conventional aptamers comprised of nucleotide (RNA and DNA) as well as peptide.

Previously, TAGCyx completed 500 million JPY Series A financing in August 2016, that enabled us to expand laboratory facility and to enforce R&D resources, and have entered into several collaboration agreements with both the Western and Japanese companies.

Achieving additional 500 million JPY fund raising, TAGCyx accelerates existing collaboration programs, partnering for the pipelines, and investing additional new projects, for early contribution to human healthcare.